Molina Healthcare vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Long Beach CA Medicaid managed care (NYSE: MOH) ~$38.7B FY2024 revenue; 5.7M members in 19 states, Medicaid redetermination management, D-SNP growth competing with Centene and Elevance.
About
Molina Healthcare, Inc. is a Long Beach, California-based managed care organization — publicly traded on the New York Stock Exchange (NYSE: MOH) as an S&P 500 Health Care component — providing Medicaid, Medicare, and Marketplace (Affordable Care Act exchange) health insurance through state-contracted managed care plans to approximately 5.7 million low-income, elderly, and disabled members across 19 states, with revenues generated primarily from per-member-per-month (PMPM) capitation payments received from state Medicaid agencies and CMS Medicare programs. In fiscal year 2024, Molina Healthcare reported revenues of approximately $38.7 billion — primarily from Medicaid capitation payments from state Medicaid agencies that contract with Molina to administer benefits for enrolled beneficiaries — generating net income impacted by elevated medical costs in the Marketplace segment as post-COVID health utilization normalization drove medical loss ratios above expectations. CEO Joseph Zubretsky's strategy of disciplined Medicaid contract renewal and Medicaid redetermination management positioned Molina for the 2023-2024 Medicaid unwinding — the federal pandemic-era continuous enrollment requirement expiration required states to redetermine eligibility for all Medicaid enrollees, with Molina proactively assisting ineligible members transition to Marketplace plans to retain the relationship. Molina's marketplace business expansion (Affordable Care Act exchange plans in new states and existing markets) provides enrollment growth offsetting Medicaid membership losses from redetermination, while Medicare Dual Eligible Special Needs Plans (D-SNPs — serving members eligible for both Medicaid and Medicare) represent the highest-growth and highest-margin Molina product line.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.